Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEKTAR THERAPEUTICSNKTR · Entity 4364 | Director · President & CEO | August 18, 2026 | August 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEKTAR THERAPEUTICS
Report date August 18, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 54,627 |
Reported balance
After 2026-08-18 transaction · row 1
1 source rowRow 1 · 2026-08-18 · Sale · Disposed 418 · Balance 54,627 F1: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2: This transaction was executed in multiple trades at prices ranging from $71.78 to $72.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. |
| Common StockSEC Table I · non-derivative | Indirectby spouse | 28 |
Reported balance
Holding disclosure · report date 2026-08-18 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 28 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person.
F2: This transaction was executed in multiple trades at prices ranging from $71.78 to $72.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 18, 2026 Filed Aug 20, 2026 23:03 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 418 | $71.98 | $30,087.64 |
DisclosureSEC source: 0001193125-26-359586 · ownership.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,627 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $71.78 to $72.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| July 24, 2026 Filed Jul 24, 2026 22:34 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 57,200 | $0.00 Strike: $15.15 | $0.00 |
DisclosureSEC source: 0001193125-26-316457 · ownership.xml · derivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,200 Underlying: Common Stock · 57,200 shares Expires 2032-12-12 F1 · security: These stock options were granted on December 13, 2024 under the 2017 Amended and Restated Performance Incentive Plan and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a monthly pro-rata basis over a period of five years from the date of grant. F2 · derivative.exercise_date: The Organization and Compensation Committee of the Board of Directors of the Issuer determined on July 23, 2026 that the performance-based vesting requirement for these stock options was satisfied and these stock options vested on July 24, 2026 (subject to remaining time-based vesting requirements). Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 23:08 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 4,500 | $61.65 | $277,425.00 |
DisclosureSEC source: 0001193125-26-276236 · ownership.xml · nonDerivative · entry 4 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,045 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026. F5 · price: This transaction was executed in multiple trades at prices ranging from $61.22 to $62.44. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 17, 2026 Filed Jun 18, 2026 23:08 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 5,500 | $60.81 | $334,455.00 |
DisclosureSEC source: 0001193125-26-276236 · ownership.xml · nonDerivative · entry 3 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,545 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026. F4 · price: This transaction was executed in multiple trades at prices ranging from $60.22 to $61.21. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 23:08 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 4,697 | $60.71 | $285,154.87 |
DisclosureSEC source: 0001193125-26-276236 · ownership.xml · nonDerivative · entry 2 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,045 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026. F3 · price: This transaction was executed in multiple trades at prices ranging from $60.37 to $61.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 23:08 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 5,303 | $59.97 | $318,020.91 |
DisclosureSEC source: 0001193125-26-276236 · ownership.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,742 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026. F2 · price: This transaction was executed in multiple trades at prices ranging from $59.35 to $60.33 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 19, 2026 Filed May 21, 2026 22:26 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 444 | $65.51 | $29,086.44 |
DisclosureSEC source: 0001193125-26-235027 · ownership.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,045 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $64.88 to $68.43. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| February 18, 2026 Filed Feb 21, 2026 00:10 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 423 | $73.00 | $30,879.00 |
DisclosureSEC source: 0001193125-26-061885 · ownership.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,489 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $72.51 to $74.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 23:01 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 86,667 | $0.00 Strike: $43.48 | $0.00 |
DisclosureSEC source: 0001193125-25-331187 · ownership.xml · derivative · entry 3 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,667 Underlying: Common Stock · 86,667 shares Expires 2033-12-21 F2 · derivative.exercise_date: Stock options vest over four years from the date of grant, (December 22, 2025) in substantially equal monthly installments based on continued service. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 23:01 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 21,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-331187 · ownership.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,912 F1 · security: Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs vest over four years from the date of grant (December 22, 2025) in substaintially equal quarterly installments based on continued service. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 01:28 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 2,207 | $54.28 | $119,795.96 |
DisclosureSEC source: 0001193125-25-297850 · ownership.xml · nonDerivative · entry 2 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,245 F3 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $58.26 to $59.56. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 21, 2025 Filed Nov 26, 2025 01:28 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 12,170 | $0.00 Strike: $281.25 | $0.00 |
DisclosureSEC source: 0001193125-25-297850 · ownership.xml · derivative · entry 4 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,170 Underlying: Common Stock · 12,170 shares Expires 2028-12-17 F5 · security: These stock options were granted on December 18, 2020 under the 2017 Plan and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a monthly pro-rata basis over a period of four years from the date of grant. F6 · derivative.exercise_date: The Compensation Committee determined on November 20, 2025 that the performance-based vesting requirement for these stock options was satisfied and these stock options vested on November 21, 2025. Read SEC document |
| November 21, 2025 Filed Nov 26, 2025 01:28 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 7,110 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-297850 · ownership.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,452 F1 · security: Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted on December 18, 2020 under the Issuer's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a quarterly pro-rata basis over a period of three years from the date of grant. F2 · date: The Organization and Compensation Committee of the Board of Directors of the Issuer ("Compensation Committee") determined on November 20, 2025 that the performance-based vesting requirement for these RSUs was satisfied and these RSUs vested on November 21, 2025. Read SEC document |
| September 09, 2025 Filed Sep 12, 2025 01:01 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 1,210 | $48.18 | $58,297.80 |
DisclosureSEC source: 0000950170-25-114365 · ownership.xml · nonDerivative · entry 4 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,342 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: This transaction was executed in multiple trades at prices ranging from $48.00 to $48.57. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 09, 2025 Filed Sep 12, 2025 01:01 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 2,156 | $47.49 | $102,388.44 |
DisclosureSEC source: 0000950170-25-114365 · ownership.xml · nonDerivative · entry 3 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,552 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $47.02 to $47.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 09, 2025 Filed Sep 12, 2025 01:01 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 1,200 | $46.41 | $55,692.00 |
DisclosureSEC source: 0000950170-25-114365 · ownership.xml · nonDerivative · entry 2 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,708 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $46.05 to $46.87. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 09, 2025 Filed Sep 12, 2025 01:01 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 2,100 | $45.16 | $94,836.00 |
DisclosureSEC source: 0000950170-25-114365 · ownership.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,908 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $45.00 to $45.41 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 05, 2025 Filed Sep 9, 2025 00:31 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 1,136 | $39.89 | $45,315.04 |
DisclosureSEC source: 0000950170-25-113691 · ownership.xml · nonDerivative · entry 7 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,008 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · price: This transaction was executed in multiple trades at prices ranging from $39.50 to $40.32. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 05, 2025 Filed Sep 9, 2025 00:31 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 2,226 | $38.82 | $86,413.32 |
DisclosureSEC source: 0000950170-25-113691 · ownership.xml · nonDerivative · entry 6 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,144 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: This transaction was executed in multiple trades at prices ranging from $38.50 to $39.37. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 05, 2025 Filed Sep 9, 2025 00:31 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 3,304 | $37.87 | $125,122.48 |
DisclosureSEC source: 0000950170-25-113691 · ownership.xml · nonDerivative · entry 5 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,370 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: This transaction was executed in multiple trades at prices ranging from $37.50 to $38.26. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 04, 2025 Filed Sep 9, 2025 00:31 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 1,134 | $35.80 | $40,597.20 |
DisclosureSEC source: 0000950170-25-113691 · ownership.xml · nonDerivative · entry 4 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,674 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: This transaction was executed in multiple trades at prices ranging from $35.35 to $36.11. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 04, 2025 Filed Sep 9, 2025 00:31 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 613 | $34.40 | $21,087.20 |
DisclosureSEC source: 0000950170-25-113691 · ownership.xml · nonDerivative · entry 3 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,808 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $34.05 to $34.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 04, 2025 Filed Sep 9, 2025 00:31 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 1,496 | $33.54 | $50,175.84 |
DisclosureSEC source: 0000950170-25-113691 · ownership.xml · nonDerivative · entry 2 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,421 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $33.02 to $33.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 04, 2025 Filed Sep 9, 2025 00:31 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 1,923 | $32.37 | $62,247.51 |
DisclosureSEC source: 0000950170-25-113691 · ownership.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,917 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $32.01 to $32.99 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 02, 2025 Filed Sep 5, 2025 01:01 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 1,500 | $30.16 | $45,240.00 |
DisclosureSEC source: 0000950170-25-113129 · ownership.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,840 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.00 to $30.30 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 19, 2025 Filed Aug 22, 2025 01:03 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 86,666 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0000950170-25-110773 · ownership.xml · derivative · entry 3 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,666 Underlying: Common Stock · 86,666 shares Expires 2031-12-12 F4 · security: These stock options were granted on December 13, 2023 under the 2017 Plan and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a monthly pro-rata basis over a period of three years from the date of grant. F5 · derivative.exercise_date: The Organization and Compensation Committee of the Board of Directors of the Issuer determined on July 17, 2025 that the performance-based vesting requirement for these stock options was satisfied and these stock options vested on August 19, 2025 (subject to remaining time-based vesting requirements). Read SEC document |
| August 19, 2025 Filed Aug 22, 2025 01:03 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 1,573 | $26.59 | $41,826.07 |
DisclosureSEC source: 0000950170-25-110773 · ownership.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,340 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $26.19 to $27.15 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. F3 · balance_after: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split. Read SEC document |
| May 19, 2025 Filed May 22, 2025 00:07 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 23,208 | $0.67 | $15,549.36 |
DisclosureSEC source: 0000950170-25-075976 · ownership.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,063,693 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $0.66 to $0.69. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 23:04 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 23,774 | $1.01 | $24,011.74 |
DisclosureSEC source: 0000950170-25-025035 · ownership.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,086,901 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $1.00 to $1.04. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 18, 2024 Filed Dec 20, 2024 02:08 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 85,035 | $0.99 | $84,184.65 |
DisclosureSEC source: 0000950170-24-138693 · ownership.xml · nonDerivative · entry 2 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,110,675 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $.93 to $1.04. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 17, 2024 Filed Dec 20, 2024 02:08 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 46,995 | $1.01 | $47,464.95 |
DisclosureSEC source: 0000950170-24-138693 · ownership.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,195,710 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $1.00 to $1.03. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 13, 2024 Filed Dec 18, 2024 01:54 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 1,300,000 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0000950170-24-137543 · ownership.xml · derivative · entry 4 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,300,000 Underlying: Common Stock · 1,300,000 shares Expires 2032-12-12 F5 · derivative.exercise_date: Stock options vest over four years from the date of grant, (December 13, 2024) in equal monthly installments based on continued service. Read SEC document |
| December 13, 2024 Filed Dec 18, 2024 01:54 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 821,250 | $0.00 Strike: $4.91 | $0.00 |
DisclosureSEC source: 0000950170-24-137543 · ownership.xml · derivative · entry 3 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 821,250 Underlying: Common Stock · 821,250 shares Expires 2030-08-14 F3 · security: These stock options were granted on August 15, 2022 under the 2017 Plan and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a monthly pro-rata basis over a period of three years from the date of grant. F4 · derivative.exercise_date: The Compensation Committee determined on November 18, 2024 that the performance-based vesting requirement for these stock options was satisfied and these stock options vested on December 13, 2024 (subject to remaining time-based vesting requirements). Read SEC document |
| December 13, 2024 Filed Dec 18, 2024 01:54 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 410,625 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-137543 · ownership.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,242,705 F1 · security: Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted on August 15, 2022 under the Issuer's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a quarterly pro-rata basis over a period of three years from the date of grant. F2 · date: The Organization and Compensation Committee of the Board of Directors of the Issuer ("Compensation Committee") determined on November 18, 2024 that the performance-based vesting requirement for these RSUs was satisfied and these RSUs vested on December 13, 2024 (subject to remaining time-based vesting requirements). Read SEC document |
| November 19, 2024 Filed Nov 21, 2024 01:36 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 16,278 | $1.01 | $16,440.78 |
DisclosureSEC source: 0000950170-24-129461 · ownership.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 832,080 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $1.00 to $1.04. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 01:14 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 14,881 | $1.28 | $19,047.68 |
DisclosureSEC source: 0000950170-24-099352 · ownership.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 848,358 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $1.24 to $1.32. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 17, 2024 Filed May 21, 2024 01:14 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 16,650 | $1.75 | $29,137.50 |
DisclosureSEC source: 0000950170-24-062646 · ownership.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 863,239 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $1.72 to $1.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| February 20, 2024 Filed Feb 23, 2024 01:16 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 20,033 | $0.68 | $13,622.44 |
DisclosureSEC source: 0000950170-24-019043 · ownership.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 879,889 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $0.66 to $0.71. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 23:05 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 1,300,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001209191-23-058859 · doc4.xml · derivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,300,000 Underlying: Common Stock · 1,300,000 shares Expires 2031-12-12 F1 · derivative.exercise_date: This stock option vests over three years from the date of grant, (December 13, 2023) in equal monthly installments based on continued service. Read SEC document |
| November 17, 2023 Filed Nov 21, 2023 01:58 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 19,877 | $0.49 | $9,739.73 |
DisclosureSEC source: 0001209191-23-056182 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 899,922 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $0.47 to $0.52. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 00:06 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 19,998 | $0.78 | $15,598.44 |
DisclosureSEC source: 0001209191-23-046460 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 919,799 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $0.75 to $0.83. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| May 16, 2023 Filed May 18, 2023 00:27 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 20,361 | $0.72 | $14,659.92 |
DisclosureSEC source: 0001209191-23-030446 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 939,797 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $0.71 to $0.75. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| February 16, 2023 Filed Feb 18, 2023 01:57 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 19,635 | $3.00 | $58,905.00 |
DisclosureSEC source: 0001209191-23-010952 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 960,158 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $2.94 to $3.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 23:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 38,014 | $3.57 | $135,709.98 |
DisclosureSEC source: 0001209191-22-057964 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 979,793 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $3.42 to $3.88. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 23:39 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 13,759 | $4.76 | $65,492.84 |
DisclosureSEC source: 0001209191-22-046486 · doc4.xml · nonDerivative · entry 2 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,017,807 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $4.67 to $4.88. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 23:39 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock · Derivative | 821,250 | $0.00 Strike: $4.91 | $0.00 |
DisclosureSEC source: 0001209191-22-046486 · doc4.xml · derivative · entry 4 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 821,250 Underlying: Common Stock · 821,250 shares Expires 2030-08-14 F4 · security: Stock options were granted in connection with a retention program and are in lieu of the Issuer's usual end-of-year annual performance grants. F5 · derivative.exercise_date: Stock options vest over three years from the date of grant in substantially equal monthly installments based on continued service. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 23:39 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 410,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-046486 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,031,566 F1 · security: Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted in connection with a retention program and are in lieu of the Issuer's usual end-of-year annual performance grants. These RSUs vest over three years from the date of grant in substantially equal quarterly installments based on continued service. Read SEC document |
| May 16, 2022 Filed May 18, 2022 01:35 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 36,529 | $3.95 | $144,289.55 |
DisclosureSEC source: 0001209191-22-029902 · doc4.xml · nonDerivative · entry 2 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 620,941 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $3.86 to $4.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. Read SEC document |
| May 15, 2022 Filed May 18, 2022 01:35 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 68,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-029902 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 657,470 F1 · security: Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted on December 14, 2018 under the Issuer's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant. F2 · date: The Organization and Compensation Committee of the Board of Directors of the Issuer determined that the performance-based vesting requirement for these RSUs was satisfied on May 13, 2022. Pursuant to the terms of the 2017 Plan, these RSUs vested on the next quarterly vesting date (May 15, 2022) following the date that the performance-based vesting requirement was satisfied. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 23:16 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 12,480 | $10.95 | $136,656.00 |
DisclosureSEC source: 0001209191-22-011438 · doc4.xml · nonDerivative · entry 1 ROBIN HOWARD W · CIK 0001206869 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 589,020 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $10.77 to $11.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.